Clinical Trial Update: A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

This entry describes a Phase Ia dose-escalation study of Sevacizumab, a humanized anti-VEGF monoclonal antibody, in patients with advanced or metastatic solid t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Sevacizumab (sevacizumab)

Snippet

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Conditions: Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Status: UNKNOWN